Showing 6291-6300 of 9848 results for "".
- Suneva Grows Their Aesthetics Portfolio with New Dealshttps://practicaldermatology.com/news/suneva-grows-their-aesthetics-portfolio-with-new-deals/2459946/Suneva® Medical, Inc., is partnering with Healeon Medical, Inc and Puregraft, LLC to add two new products to their a
- Bristol-Myers Squibb to Acquire Celgenehttps://practicaldermatology.com/news/bristol-myers-squibb-to-acquire-celgene/2459948/Bristol-Myers Squibb Company will acquire Celgene Corp. in a cash and stock transaction with an equity value of approximately $74 billion. The combined company with complementary areas of focus, will opera
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G
- National Rosacea Society: New Grants Available in 2019https://practicaldermatology.com/news/national-rosacea-society-new-grants-available-in-2019/2457536/The National Rosacea Society (NRS) has new grants available in 2019 to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention, or potential cure. The deadline for submitting proposals for research grants in 2019 is
- Glenmark Pharmaceuticals Enters US Branded Dermatology Segmenthttps://practicaldermatology.com/news/glenmark-pharmaceuticals-enters-us-branded-dermatology-segment/2457537/Glenmark Pharmaceuticals is entering into the branded dermatology segment in the United States. The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA. This represents an imp
- Rio Professor Develops Sunscreen for Hairhttps://practicaldermatology.com/news/rio-professor-develops-sunscreen-for-hair/2457538/A Rio professor and her team of students have developed the first national product capable of protecting hair from sun radiation. According to Ana Percebom, of the Scientific Technical Center of University PUC in Rio, none of the products currently sold have substances that actually block
- New Study Seeks to Improve Skin Cancer Prevention in Young Adults Via a New Websitehttps://practicaldermatology.com/news/new-study-seeks-to-improve-skin-cancer-prevention-in-young-adults-via-a-new-website/2457539/Researchers out of Rutgers Cancer Institute of New Jersey and colleagues from across the country are conducting a study to evaluate the reach and effectiveness of an online program targeted at skin cancer prevention in young adults. Investigators are refining an existing website to
- RealSelf Forms Strategic Medical Advisory Councilhttps://practicaldermatology.com/news/realself-forms-strategic-medical-advisory-council/2457540/RealSelf, Inc. has formed a Strategic Medical Advisory Council with three operating boards. The RealSelf Strategic Advisory Council is made up of the Business Advisory Board, the Medical Review Advisory Board and the Industry Advisory Board, all of which are comprised of board-certified doctors a
- New Study Investigates Prurigo Nodularis Treatmentshttps://practicaldermatology.com/news/new-study-investigates-prurigo-nodularis-treatments/2457542/Emerging treatments such as neurokinin-1 receptor antagonists show the most promise for prurigo nodularis, according to a review in JAMA Dermatology. Neurokinin-1 receptor is a target of substance P, a medi